TANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury

Abstract We aimed to elucidate the differences in genomic methylation patterns between ADLI and non-ADLI patients to identify DNA methylation-based biomarkers. Genome-wide DNA methylation patterns were obtained using Infinium MethylationEPIC (EPIC) BeadChip array to analyze 14 peripheral blood sampl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dongxue Wu, Yuhong Li, Qi Ren, Shengfei Pei, Lin Wang, Luming Yang, Yingzhi Chong, Shufeng Sun, Jinqi Hao, Fumin Feng
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ac6f454b3c8b4e6b87aa2006aabf0d38
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ac6f454b3c8b4e6b87aa2006aabf0d38
record_format	dspace
spelling	oai:doaj.org-article:ac6f454b3c8b4e6b87aa2006aabf0d382021-12-02T17:51:31ZTANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury10.1038/s41598-021-96869-52045-2322https://doaj.org/article/ac6f454b3c8b4e6b87aa2006aabf0d382021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96869-5https://doaj.org/toc/2045-2322Abstract We aimed to elucidate the differences in genomic methylation patterns between ADLI and non-ADLI patients to identify DNA methylation-based biomarkers. Genome-wide DNA methylation patterns were obtained using Infinium MethylationEPIC (EPIC) BeadChip array to analyze 14 peripheral blood samples (7 ADLI cases, 7 non-ADLI controls). Changes in the mRNA and DNA methylation in the target genes of another 120 peripheral blood samples (60 ADLI cases, 60 non-ADLI controls) were analyzed by real-time polymerase chain reaction and pyrosequencing, respectively. A total of 308 hypermethylated CpG sites and 498 hypomethylated CpG sites were identified. Significantly, hypermethylated CpG sites cg06961147 and cg24666046 in TANC1 associated with ADLI was identified by genome-wide DNA methylation profiling. The mRNA expression of TANC1 was lower in the cases compared to the controls. Pyrosequencing validated these two differentially methylated loci, which was consistent with the results from the EPIC BeadChip array. Receiver operating characteristic analysis indicated that the area under the curve of TANC1 (cg06961147, cg24666046, and their combinations) was 0.812, 0.842, and 0.857, respectively. These results indicate that patients with ADLI have different genomic methylation patterns than patients without ADLI. The hypermethylated differentially methylated site cg06961147 combined with cg24666046 in TANC1 provides evidence for the diagnosis of ADLI.Dongxue WuYuhong LiQi RenShengfei PeiLin WangLuming YangYingzhi ChongShufeng SunJinqi HaoFumin FengNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Dongxue Wu Yuhong Li Qi Ren Shengfei Pei Lin Wang Luming Yang Yingzhi Chong Shufeng Sun Jinqi Hao Fumin Feng TANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury
description	Abstract We aimed to elucidate the differences in genomic methylation patterns between ADLI and non-ADLI patients to identify DNA methylation-based biomarkers. Genome-wide DNA methylation patterns were obtained using Infinium MethylationEPIC (EPIC) BeadChip array to analyze 14 peripheral blood samples (7 ADLI cases, 7 non-ADLI controls). Changes in the mRNA and DNA methylation in the target genes of another 120 peripheral blood samples (60 ADLI cases, 60 non-ADLI controls) were analyzed by real-time polymerase chain reaction and pyrosequencing, respectively. A total of 308 hypermethylated CpG sites and 498 hypomethylated CpG sites were identified. Significantly, hypermethylated CpG sites cg06961147 and cg24666046 in TANC1 associated with ADLI was identified by genome-wide DNA methylation profiling. The mRNA expression of TANC1 was lower in the cases compared to the controls. Pyrosequencing validated these two differentially methylated loci, which was consistent with the results from the EPIC BeadChip array. Receiver operating characteristic analysis indicated that the area under the curve of TANC1 (cg06961147, cg24666046, and their combinations) was 0.812, 0.842, and 0.857, respectively. These results indicate that patients with ADLI have different genomic methylation patterns than patients without ADLI. The hypermethylated differentially methylated site cg06961147 combined with cg24666046 in TANC1 provides evidence for the diagnosis of ADLI.
format	article
author	Dongxue Wu Yuhong Li Qi Ren Shengfei Pei Lin Wang Luming Yang Yingzhi Chong Shufeng Sun Jinqi Hao Fumin Feng
author_facet	Dongxue Wu Yuhong Li Qi Ren Shengfei Pei Lin Wang Luming Yang Yingzhi Chong Shufeng Sun Jinqi Hao Fumin Feng
author_sort	Dongxue Wu
title	TANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury
title_short	TANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury
title_full	TANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury
title_fullStr	TANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury
title_full_unstemmed	TANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury
title_sort	tanc1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ac6f454b3c8b4e6b87aa2006aabf0d38
work_keys_str_mv	AT dongxuewu tanc1methylationasanovelbiomarkerforthediagnosisofpatientswithantituberculosisdruginducedliverinjury AT yuhongli tanc1methylationasanovelbiomarkerforthediagnosisofpatientswithantituberculosisdruginducedliverinjury AT qiren tanc1methylationasanovelbiomarkerforthediagnosisofpatientswithantituberculosisdruginducedliverinjury AT shengfeipei tanc1methylationasanovelbiomarkerforthediagnosisofpatientswithantituberculosisdruginducedliverinjury AT linwang tanc1methylationasanovelbiomarkerforthediagnosisofpatientswithantituberculosisdruginducedliverinjury AT lumingyang tanc1methylationasanovelbiomarkerforthediagnosisofpatientswithantituberculosisdruginducedliverinjury AT yingzhichong tanc1methylationasanovelbiomarkerforthediagnosisofpatientswithantituberculosisdruginducedliverinjury AT shufengsun tanc1methylationasanovelbiomarkerforthediagnosisofpatientswithantituberculosisdruginducedliverinjury AT jinqihao tanc1methylationasanovelbiomarkerforthediagnosisofpatientswithantituberculosisdruginducedliverinjury AT fuminfeng tanc1methylationasanovelbiomarkerforthediagnosisofpatientswithantituberculosisdruginducedliverinjury
_version_	1718379247119106048

TANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury

Ejemplares similares